| name | managing-specimen-integrity |
| description | Evaluates specimen adequacy and rejection criteria with pre-analytical quality documentation. Use when assessing specimen quality, documenting rejection reasons, or managing pre-analytical errors. |
| tags | ["management","pathology"] |
| metadata | {"author":"casemark","practice_areas":["Pathology","Laboratory Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]} |
Managing Specimen Integrity
Evaluates specimen adequacy and rejection criteria with pre-analytical quality documentation.
Why This Skill Exists
Pre-analytical errors account for 46-68% of all laboratory errors, and specimen integrity failures are the leading cause. A hemolyzed potassium specimen, a clotted coagulation tube, an unlabeled surgical specimen, or an improperly transported microbiology culture can each produce misleading results that drive incorrect clinical decisions. The economic cost is substantial: recollection disrupts clinical workflows, delays diagnosis, and in some cases (neonatal, oncology, difficult-access patients) recollection may be impossible or harmful.
CLIA 42 CFR 493.1242 requires laboratories to establish specimen submission and handling instructions and define criteria for specimen rejection. CAP accreditation (GEN.40490-40530 series) mandates documented acceptance/rejection criteria, specimen labeling requirements (two patient identifiers), and processes for managing non-conforming specimens. The Joint Commission patient safety goals reinforce two-identifier specimen labeling. This skill provides a systematic framework for evaluating specimen integrity and managing pre-analytical quality.
Checkpoint A: Pre-Draft Intake (Mandatory)
- Specimen type — Blood (tube type), urine, tissue, body fluid, swab, or other? Default: blood specimen.
- Test(s) ordered — What analytes are requested? Different tests have different integrity requirements. Default: comprehensive metabolic panel.
- Issue identified — Hemolysis, lipemia, icterus, clotting, underfill, mislabel, wrong tube, delayed transport, temperature excursion, or other? Default: hemolysis.
- Patient context — Difficult draw (neonatal, dialysis, oncology), repeated collection issue, stat/urgent request? Default: routine adult.
- Collection site — Was the specimen drawn from an IV line, port, or direct venipuncture? Default: direct venipuncture.
- Time since collection — How long has the specimen been in transit or storage? Default: < 2 hours.
- Recollection feasibility — Can a new specimen be obtained without significant burden? Default: yes.
Documents to Request
- Specimen requisition form with two identifiers
- Collection time and collector identity
- Transport conditions (temperature, time in transit)
- Tube type and anticoagulant verification
- Hemolysis/lipemia/icterus index from analyzer (if quantified)
- Institutional specimen acceptance/rejection criteria policy
- Test-specific specimen requirements (stability, tube type, volume)
- Non-conforming specimen log
Step 1: Specimen Identification and Labeling Verification
Verify specimen labeling per CAP and Joint Commission requirements:
Minimum labeling requirements (CAP GEN.40490):
- Two unique patient identifiers (name + DOB, name + MRN, or equivalent)
- Date of collection
- Time of collection (required for time-sensitive analytes)
- Collector identification
- Specimen source/type (for non-blood specimens)
Rejection criteria for labeling deficiencies:
| Deficiency | Action |
|---|
| No label on specimen | REJECT — no exceptions. Specimen cannot be relabeled after leaving the patient. |
| One identifier only | REJECT — recollect. Two identifiers are non-negotiable per Joint Commission NPSG. |
| Label on container but not on tube | REJECT — the tube itself must be labeled, not just an accompanying form. |
| Discrepancy between label and requisition | HOLD — contact collector for resolution before processing. |
| Illegible label | HOLD — contact collector for verification; reject if unresolvable. |
Exception: Surgical pathology and cytology specimens may have a reconciliation process per CAP ANP.11700, but the two-identifier requirement still applies.
Step 2: Specimen Condition Assessment
Evaluate the physical condition of the specimen:
Hemolysis Index (Chemistry Analyzers)
| H-Index | Hemolysis Level | Affected Analytes | Action |
|---|
| H < 50 | None/slight | None significantly | Process normally |
| H 50-100 | Mild | Potassium (+), LDH (+), AST (+), iron (+) | Report with comment for mildly affected analytes |
| H 100-200 | Moderate | K, LDH, AST, iron, total bilirubin, phosphorus | Reject affected analytes; report unaffected |
| H > 200 | Gross | Most chemistry analytes affected | Reject specimen; recollect |
Lipemia Index
| L-Index | Lipemia Level | Affected Analytes | Action |
|---|
| L < 150 | None/slight | None significantly | Process normally |
| L 150-300 | Moderate | Electrolytes (pseudohyponatremia), some enzymes | Report with comment |
| L > 300 | Gross | Many analytes affected by light scattering | Ultracentrifuge or reject |
Icterus Index
| I-Index | Icterus Level | Affected Analytes | Action |
|---|
| I < 20 | None/slight | None significantly | Process normally |
| I 20-40 | Moderate | Creatinine (Jaffe method), some enzymatic assays | Report with comment |
| I > 40 | Marked | Multiple analytes affected | Report with interference note |
Step 3: Tube Type and Volume Verification
Confirm correct tube type and adequate fill volume:
Common tube types and requirements:
| Tube Color (Cap) | Additive | Tests | Minimum Fill |
|---|
| Light blue (citrate) | 3.2% sodium citrate | PT, PTT, fibrinogen, coag factors | 90% fill (9:1 blood:citrate ratio); underfill produces falsely prolonged results |
| Lavender (EDTA) | K2EDTA or K3EDTA | CBC, differential, reticulocyte, HbA1c | Minimum 0.5 mL for CBC |
| Green (heparin) | Lithium heparin or sodium heparin | Stat chemistry, ammonia | Per tube manufacturer |
| Gold/red (SST/no additive) | Clot activator +/- gel | Routine chemistry, serology, drug levels | Allow 30 min clotting before centrifugation |
| Gray (NaF/oxalate) | Sodium fluoride/potassium oxalate | Glucose, lactate | Per tube manufacturer |
Rejection criteria for tube/volume issues:
| Issue | Action |
|---|
| Citrate tube < 90% filled | REJECT for coagulation tests. Insufficient fill alters the blood:citrate ratio. |
| Clotted EDTA specimen | REJECT for CBC. Platelet count will be falsely low. |
| Wrong tube type for test | REJECT — do not attempt to process. |
| Specimen drawn from IV line without discard | REJECT — risk of dilution or contamination with IV fluids. |
Step 4: Stability and Transport Assessment
Evaluate whether specimen stability requirements were met:
Critical stability windows:
| Analyte/Test | Room Temp Stability | Refrigerated Stability | Special Requirements |
|---|
| Potassium | 4 hours (separate from cells) | 24 hours (after separation) | Must centrifuge within 1 hour; pseudohyperkalemia if delayed |
| Glucose (no NaF) | 30 minutes | 2 hours | Glycolysis reduces glucose ~7%/hour at room temp |
| Ammonia | 15 minutes on ice | 15 minutes on ice | Must be transported on ice and centrifuged immediately |
| Blood gas (ABG) | 15 minutes (plastic syringe) | 30 minutes (glass syringe, ice) | Air bubbles invalidate pO2/pCO2 |
| Lactic acid | 15 minutes on ice | 15 minutes on ice | Tourniquet time and fist clenching cause false elevation |
| Coagulation (PT, PTT) | 4 hours at RT (uncentrifuged) | 24 hours (centrifuged, frozen) | Do not refrigerate uncentrifuged citrate tubes |
| CSF cell count | 1 hour | 1 hour | WBCs lyse rapidly; process stat |
Step 5: Non-Conforming Specimen Management and Documentation
When a specimen is rejected or has quality issues, follow a structured process:
- Document the issue: Record the specific non-conformance (hemolysis, clot, mislabel, etc.) in the LIS.
- Notify the collector/ordering provider: Per institutional policy, communicate the rejection reason and recollection instructions.
- Partial reporting: When possible, report unaffected analytes from the specimen and reject only those analytes affected by the integrity issue. Add interpretive comments.
- Log the non-conformance: Enter into the non-conforming specimen tracking system for trending.
- Trend analysis: Review non-conformance data monthly. Identify patterns by collector, unit, specimen type, or time of day. Target QI interventions to reduce the most common and impactful errors.
- Education and feedback: Provide targeted education to collection staff when trends are identified. Document training and re-competency assessment.
Checkpoint B: Post-Draft Alignment (Mandatory)
- Was specimen labeling verified against the two-identifier requirement before any testing?
- Were hemolysis, lipemia, and icterus indices quantified and applied to analyte-specific rejection criteria?
- Was tube type confirmed as correct for all ordered tests?
- Were stability requirements assessed based on collection time and transport conditions?
- Was the non-conforming specimen documented in the tracking system with collector notification?
Quality Audit
Guidelines
- Never process an unlabeled specimen regardless of urgency — this is a non-negotiable patient safety requirement per CAP and Joint Commission
- Quantify hemolysis, lipemia, and icterus using the analyzer's serum index system rather than visual estimation; visual assessment is unreliable and not auditable
- Apply analyte-specific rejection thresholds rather than blanket specimen rejection; many analytes are unaffected by mild hemolysis, and rejecting the entire panel wastes clinical resources
- For citrate tubes (coagulation testing), reject any tube less than 90% filled; the altered blood-to-citrate ratio produces unreliable PT and PTT results regardless of how "close" the fill appears
- Separate serum/plasma from cells within 1 hour of collection for potassium and other cell-sensitive analytes; delayed separation is the most common cause of pseudohyperkalemia
- Track non-conforming specimens by collector, unit, and specimen type; use the data for targeted quality improvement rather than punitive action
- When recollection is impossible or poses significant patient burden (neonatal, difficult access), consult with the laboratory director about reporting with appropriate qualifiers and comments
- Review and update institutional acceptance/rejection criteria at least annually and whenever new tests or specimen types are introduced
